Showing results (61-70 of 131) with videos related to
Sort By:
Pageof 14
Hepatology International|March 20, 2015
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 yearsMaria Buti, Scott Fung, Edward Gane, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.Cell Reports. Medicine|April 19, 2023
Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASHJake Conway, Maryam Pouryahya, Yevgeniy Gindin, et al.Lancet (London, England)|December 14, 2012
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyPatrick Marcellin, Edward Gane, Maria Buti, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing CholangitisPalak J Trivedi, Andrew J Muir, Cynthia Levy, et al.Gastroenterology|January 30, 2018
TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide AnaloguesCarolina Boni, Andrea Vecchi, Marzia Rossi, et al.Antiviral Therapy|March 8, 2006
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapyVijayan Balan, David R Nelson, Mark S Sulkowski, et al.Gastroenterology|January 28, 2014
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNAHenry L Y Chan, Chi Kuen Chan, Aric Josun Hui, et al.Journal of Hepatology|August 24, 2024
ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASHYasmine J Liu, Masaki Kimura, Xiaoxu Li, et al.Hepatology (Baltimore, Md.)|September 12, 2017
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trialRohit Loomba, Eric Lawitz, Parvez S Mantry, et al.Pageof 14